| Haven Home Health Care | |
| 1280 South 20th Avenue, Suite A, Safford, Arizona 85546 | |
| (734) 560-8953 | |
| Not Available |
| Name | Haven Home Health Care |
|---|---|
| Location | 1280 South 20th Avenue, Suite A, Safford, Arizona |
| Certified By | Medicare |
| Services Offered | Nursing Care Physical Therapy Occupational Therapy Speech Pathology Medical Social Services Home Health Aide |
| Medicare ID | 37494 |
| Ownership Type | Proprietary |
| Service Area Zip Codes |
| NPI Number | 1003976705 |
| Organization Name | ATLANTIC HOME HEALTH CARE, LLC |
| Address | 1280 S 20th Ave Ste A, Safford, AZ 85546 |
| Phone Number | 928-792-4354 |
News Archive
In a new study published online in Biological Psychiatry on January 16, 2015, researchers from Butler Hospital identify an association between biological changes on the cellular level and both childhood adversity and psychiatric disorders.
Interstage Home Monitoring (IHM) programs for infants with single ventricle heart defects help families recognize potential complications early and improve infant survival rates and growth prior to the second of multiple surgeries.
The U.S. Food and Drug Administration today approved the VisuMax Femtosecond Laser for the small incision lenticule extraction (SMILE) procedure to reduce or eliminate nearsightedness in certain patients 22 years of age or older.
Scientists at The Scripps Research Institute have found what may be a major cause of congenital hydrocephalus, one of the most common neurological disorders of childhood that produces mental debilitation and sometimes death in premature and newborn children.
Rare Disease Therapeutics, Inc. (RDT), the producer of orphan pharmaceuticals for the treatment of rare diseases, announced today that they have received FDA approval for PURIXAN™ (mercaptopurine) 20 mg/mL oral suspension--a new, easier-to-dose, liquid form of an established treatment for patients with Acute Lymphoblastic Leukemia (ALL).
› Verified 6 days ago
| NPI Number | 1063119154 |
| Organization Name | HAVEN EEOI HOLDINGS LLC |
| Address | 800 S Gay St Ste 701, Knoxville, TN 37929 |
| Phone Number | 888-891-0786 |
News Archive
In a new study published online in Biological Psychiatry on January 16, 2015, researchers from Butler Hospital identify an association between biological changes on the cellular level and both childhood adversity and psychiatric disorders.
Interstage Home Monitoring (IHM) programs for infants with single ventricle heart defects help families recognize potential complications early and improve infant survival rates and growth prior to the second of multiple surgeries.
The U.S. Food and Drug Administration today approved the VisuMax Femtosecond Laser for the small incision lenticule extraction (SMILE) procedure to reduce or eliminate nearsightedness in certain patients 22 years of age or older.
Scientists at The Scripps Research Institute have found what may be a major cause of congenital hydrocephalus, one of the most common neurological disorders of childhood that produces mental debilitation and sometimes death in premature and newborn children.
Rare Disease Therapeutics, Inc. (RDT), the producer of orphan pharmaceuticals for the treatment of rare diseases, announced today that they have received FDA approval for PURIXAN™ (mercaptopurine) 20 mg/mL oral suspension--a new, easier-to-dose, liquid form of an established treatment for patients with Acute Lymphoblastic Leukemia (ALL).
› Verified 6 days ago
| NPI Number | 1154027043 |
| Organization Name | HAVEN EEOI HOLDINGS LLC |
| Address | 950 W Bannock St Ste 1100, Boise, ID 83702 |
| Phone Number | 888-891-0786 |
News Archive
In a new study published online in Biological Psychiatry on January 16, 2015, researchers from Butler Hospital identify an association between biological changes on the cellular level and both childhood adversity and psychiatric disorders.
Interstage Home Monitoring (IHM) programs for infants with single ventricle heart defects help families recognize potential complications early and improve infant survival rates and growth prior to the second of multiple surgeries.
The U.S. Food and Drug Administration today approved the VisuMax Femtosecond Laser for the small incision lenticule extraction (SMILE) procedure to reduce or eliminate nearsightedness in certain patients 22 years of age or older.
Scientists at The Scripps Research Institute have found what may be a major cause of congenital hydrocephalus, one of the most common neurological disorders of childhood that produces mental debilitation and sometimes death in premature and newborn children.
Rare Disease Therapeutics, Inc. (RDT), the producer of orphan pharmaceuticals for the treatment of rare diseases, announced today that they have received FDA approval for PURIXAN™ (mercaptopurine) 20 mg/mL oral suspension--a new, easier-to-dose, liquid form of an established treatment for patients with Acute Lymphoblastic Leukemia (ALL).
› Verified 6 days ago
| NPI Number | 1154915015 |
| Organization Name | HOME HEALTH SAFFORD, LLC |
| Doing Business As | HAVEN HOME HEALTH CARE |
| Address | 1280 S 20th Ave Ste A2, Safford, AZ 85546 |
| Phone Number | 888-891-0786 |
News Archive
In a new study published online in Biological Psychiatry on January 16, 2015, researchers from Butler Hospital identify an association between biological changes on the cellular level and both childhood adversity and psychiatric disorders.
Interstage Home Monitoring (IHM) programs for infants with single ventricle heart defects help families recognize potential complications early and improve infant survival rates and growth prior to the second of multiple surgeries.
The U.S. Food and Drug Administration today approved the VisuMax Femtosecond Laser for the small incision lenticule extraction (SMILE) procedure to reduce or eliminate nearsightedness in certain patients 22 years of age or older.
Scientists at The Scripps Research Institute have found what may be a major cause of congenital hydrocephalus, one of the most common neurological disorders of childhood that produces mental debilitation and sometimes death in premature and newborn children.
Rare Disease Therapeutics, Inc. (RDT), the producer of orphan pharmaceuticals for the treatment of rare diseases, announced today that they have received FDA approval for PURIXAN™ (mercaptopurine) 20 mg/mL oral suspension--a new, easier-to-dose, liquid form of an established treatment for patients with Acute Lymphoblastic Leukemia (ALL).
› Verified 6 days ago
| NPI Number | 1154941813 |
| Organization Name | ATLANTIC HOME HEALTH CARE, LLC |
| Address | 201 W Lakeway Rd, Gillette, WY 82718 |
| Phone Number | 888-891-0786 |
News Archive
In a new study published online in Biological Psychiatry on January 16, 2015, researchers from Butler Hospital identify an association between biological changes on the cellular level and both childhood adversity and psychiatric disorders.
Interstage Home Monitoring (IHM) programs for infants with single ventricle heart defects help families recognize potential complications early and improve infant survival rates and growth prior to the second of multiple surgeries.
The U.S. Food and Drug Administration today approved the VisuMax Femtosecond Laser for the small incision lenticule extraction (SMILE) procedure to reduce or eliminate nearsightedness in certain patients 22 years of age or older.
Scientists at The Scripps Research Institute have found what may be a major cause of congenital hydrocephalus, one of the most common neurological disorders of childhood that produces mental debilitation and sometimes death in premature and newborn children.
Rare Disease Therapeutics, Inc. (RDT), the producer of orphan pharmaceuticals for the treatment of rare diseases, announced today that they have received FDA approval for PURIXAN™ (mercaptopurine) 20 mg/mL oral suspension--a new, easier-to-dose, liquid form of an established treatment for patients with Acute Lymphoblastic Leukemia (ALL).
› Verified 6 days ago
| NPI Number | 1225729452 |
| Organization Name | MHC AREA 3, LLC |
| Address | 3320 Sw 33rd Rd Ste 100, Ocala, FL 34474 |
| Phone Number | 888-891-0786 |
News Archive
In a new study published online in Biological Psychiatry on January 16, 2015, researchers from Butler Hospital identify an association between biological changes on the cellular level and both childhood adversity and psychiatric disorders.
Interstage Home Monitoring (IHM) programs for infants with single ventricle heart defects help families recognize potential complications early and improve infant survival rates and growth prior to the second of multiple surgeries.
The U.S. Food and Drug Administration today approved the VisuMax Femtosecond Laser for the small incision lenticule extraction (SMILE) procedure to reduce or eliminate nearsightedness in certain patients 22 years of age or older.
Scientists at The Scripps Research Institute have found what may be a major cause of congenital hydrocephalus, one of the most common neurological disorders of childhood that produces mental debilitation and sometimes death in premature and newborn children.
Rare Disease Therapeutics, Inc. (RDT), the producer of orphan pharmaceuticals for the treatment of rare diseases, announced today that they have received FDA approval for PURIXAN™ (mercaptopurine) 20 mg/mL oral suspension--a new, easier-to-dose, liquid form of an established treatment for patients with Acute Lymphoblastic Leukemia (ALL).
› Verified 6 days ago
| NPI Number | 1467131375 |
| Organization Name | VCG ARIZONA LLC |
| Address | 1280 S 20th Ave Ste A2, Safford, AZ 85546 |
| Phone Number | 903-787-7609 |
News Archive
In a new study published online in Biological Psychiatry on January 16, 2015, researchers from Butler Hospital identify an association between biological changes on the cellular level and both childhood adversity and psychiatric disorders.
Interstage Home Monitoring (IHM) programs for infants with single ventricle heart defects help families recognize potential complications early and improve infant survival rates and growth prior to the second of multiple surgeries.
The U.S. Food and Drug Administration today approved the VisuMax Femtosecond Laser for the small incision lenticule extraction (SMILE) procedure to reduce or eliminate nearsightedness in certain patients 22 years of age or older.
Scientists at The Scripps Research Institute have found what may be a major cause of congenital hydrocephalus, one of the most common neurological disorders of childhood that produces mental debilitation and sometimes death in premature and newborn children.
Rare Disease Therapeutics, Inc. (RDT), the producer of orphan pharmaceuticals for the treatment of rare diseases, announced today that they have received FDA approval for PURIXAN™ (mercaptopurine) 20 mg/mL oral suspension--a new, easier-to-dose, liquid form of an established treatment for patients with Acute Lymphoblastic Leukemia (ALL).
› Verified 6 days ago
| NPI Number | 1558008375 |
| Organization Name | HOME HEALTH SHOW LOW, LLC |
| Address | 5658 Highway 260 Ste 21, Lakeside, AZ 85929 |
| Phone Number | 888-891-0786 |
News Archive
In a new study published online in Biological Psychiatry on January 16, 2015, researchers from Butler Hospital identify an association between biological changes on the cellular level and both childhood adversity and psychiatric disorders.
Interstage Home Monitoring (IHM) programs for infants with single ventricle heart defects help families recognize potential complications early and improve infant survival rates and growth prior to the second of multiple surgeries.
The U.S. Food and Drug Administration today approved the VisuMax Femtosecond Laser for the small incision lenticule extraction (SMILE) procedure to reduce or eliminate nearsightedness in certain patients 22 years of age or older.
Scientists at The Scripps Research Institute have found what may be a major cause of congenital hydrocephalus, one of the most common neurological disorders of childhood that produces mental debilitation and sometimes death in premature and newborn children.
Rare Disease Therapeutics, Inc. (RDT), the producer of orphan pharmaceuticals for the treatment of rare diseases, announced today that they have received FDA approval for PURIXAN™ (mercaptopurine) 20 mg/mL oral suspension--a new, easier-to-dose, liquid form of an established treatment for patients with Acute Lymphoblastic Leukemia (ALL).
› Verified 6 days ago
| NPI Number | 1720704190 |
| Organization Name | HAVEN EEOI HOLDINGS LLC |
| Doing Business As | HAVEN HOME HEALTH CARE |
| Address | 16165 N 83rd Ave Ste 200, Peoria, AZ 85382 |
| Phone Number | 888-891-0786 |
News Archive
In a new study published online in Biological Psychiatry on January 16, 2015, researchers from Butler Hospital identify an association between biological changes on the cellular level and both childhood adversity and psychiatric disorders.
Interstage Home Monitoring (IHM) programs for infants with single ventricle heart defects help families recognize potential complications early and improve infant survival rates and growth prior to the second of multiple surgeries.
The U.S. Food and Drug Administration today approved the VisuMax Femtosecond Laser for the small incision lenticule extraction (SMILE) procedure to reduce or eliminate nearsightedness in certain patients 22 years of age or older.
Scientists at The Scripps Research Institute have found what may be a major cause of congenital hydrocephalus, one of the most common neurological disorders of childhood that produces mental debilitation and sometimes death in premature and newborn children.
Rare Disease Therapeutics, Inc. (RDT), the producer of orphan pharmaceuticals for the treatment of rare diseases, announced today that they have received FDA approval for PURIXAN™ (mercaptopurine) 20 mg/mL oral suspension--a new, easier-to-dose, liquid form of an established treatment for patients with Acute Lymphoblastic Leukemia (ALL).
› Verified 6 days ago
| NPI Number | 1841989258 |
| Organization Name | HAVEN EEOI HOLDINGS LLC |
| Address | 885 Penniman Ave Unit 6426, Plymouth, MI 48170 |
| Phone Number | 888-891-0786 |
News Archive
In a new study published online in Biological Psychiatry on January 16, 2015, researchers from Butler Hospital identify an association between biological changes on the cellular level and both childhood adversity and psychiatric disorders.
Interstage Home Monitoring (IHM) programs for infants with single ventricle heart defects help families recognize potential complications early and improve infant survival rates and growth prior to the second of multiple surgeries.
The U.S. Food and Drug Administration today approved the VisuMax Femtosecond Laser for the small incision lenticule extraction (SMILE) procedure to reduce or eliminate nearsightedness in certain patients 22 years of age or older.
Scientists at The Scripps Research Institute have found what may be a major cause of congenital hydrocephalus, one of the most common neurological disorders of childhood that produces mental debilitation and sometimes death in premature and newborn children.
Rare Disease Therapeutics, Inc. (RDT), the producer of orphan pharmaceuticals for the treatment of rare diseases, announced today that they have received FDA approval for PURIXAN™ (mercaptopurine) 20 mg/mL oral suspension--a new, easier-to-dose, liquid form of an established treatment for patients with Acute Lymphoblastic Leukemia (ALL).
› Verified 6 days ago
| NPI Number | 1922611243 |
| Organization Name | ATLANTIC HOME HEALTH CARE, LLC |
| Address | 131 Stony Cir, Santa Rosa, CA 95401 |
| Phone Number | 888-891-0786 |
News Archive
In a new study published online in Biological Psychiatry on January 16, 2015, researchers from Butler Hospital identify an association between biological changes on the cellular level and both childhood adversity and psychiatric disorders.
Interstage Home Monitoring (IHM) programs for infants with single ventricle heart defects help families recognize potential complications early and improve infant survival rates and growth prior to the second of multiple surgeries.
The U.S. Food and Drug Administration today approved the VisuMax Femtosecond Laser for the small incision lenticule extraction (SMILE) procedure to reduce or eliminate nearsightedness in certain patients 22 years of age or older.
Scientists at The Scripps Research Institute have found what may be a major cause of congenital hydrocephalus, one of the most common neurological disorders of childhood that produces mental debilitation and sometimes death in premature and newborn children.
Rare Disease Therapeutics, Inc. (RDT), the producer of orphan pharmaceuticals for the treatment of rare diseases, announced today that they have received FDA approval for PURIXAN™ (mercaptopurine) 20 mg/mL oral suspension--a new, easier-to-dose, liquid form of an established treatment for patients with Acute Lymphoblastic Leukemia (ALL).
› Verified 6 days ago
| Quality Rating: | Not Available* |
| * This measure currently does not have data or provider has been certified/recertified for less than 6 months. | |
News Archive
In a new study published online in Biological Psychiatry on January 16, 2015, researchers from Butler Hospital identify an association between biological changes on the cellular level and both childhood adversity and psychiatric disorders.
Interstage Home Monitoring (IHM) programs for infants with single ventricle heart defects help families recognize potential complications early and improve infant survival rates and growth prior to the second of multiple surgeries.
The U.S. Food and Drug Administration today approved the VisuMax Femtosecond Laser for the small incision lenticule extraction (SMILE) procedure to reduce or eliminate nearsightedness in certain patients 22 years of age or older.
Scientists at The Scripps Research Institute have found what may be a major cause of congenital hydrocephalus, one of the most common neurological disorders of childhood that produces mental debilitation and sometimes death in premature and newborn children.
Rare Disease Therapeutics, Inc. (RDT), the producer of orphan pharmaceuticals for the treatment of rare diseases, announced today that they have received FDA approval for PURIXAN™ (mercaptopurine) 20 mg/mL oral suspension--a new, easier-to-dose, liquid form of an established treatment for patients with Acute Lymphoblastic Leukemia (ALL).
› Verified 6 days ago
News Archive
In a new study published online in Biological Psychiatry on January 16, 2015, researchers from Butler Hospital identify an association between biological changes on the cellular level and both childhood adversity and psychiatric disorders.
Interstage Home Monitoring (IHM) programs for infants with single ventricle heart defects help families recognize potential complications early and improve infant survival rates and growth prior to the second of multiple surgeries.
The U.S. Food and Drug Administration today approved the VisuMax Femtosecond Laser for the small incision lenticule extraction (SMILE) procedure to reduce or eliminate nearsightedness in certain patients 22 years of age or older.
Scientists at The Scripps Research Institute have found what may be a major cause of congenital hydrocephalus, one of the most common neurological disorders of childhood that produces mental debilitation and sometimes death in premature and newborn children.
Rare Disease Therapeutics, Inc. (RDT), the producer of orphan pharmaceuticals for the treatment of rare diseases, announced today that they have received FDA approval for PURIXAN™ (mercaptopurine) 20 mg/mL oral suspension--a new, easier-to-dose, liquid form of an established treatment for patients with Acute Lymphoblastic Leukemia (ALL).
› Verified 6 days ago
Eden Home Health Location: 1491 West Thatcher Boulevard, Suite 104, Safford, Arizona 85546 Ratings: Phone: (520) 335-6118 | |
Haven Home Health Care Location: 1280 South 20th Avenue, Suite A, Safford, Arizona 85546 Ratings: NA Phone: (734) 560-8953 |